Business
Arcutis Announces Positive Topline Data from Phase 2 Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis
Roflumilast foam demonstrated statistically significant improvement over the vehicle foam on the trial’s primary and multiple secondary endpointsOnce-daily
About this update from Arcutis Biotherapeutics, Inc.
[{"type":"text","content":"Roflumilast foam demonstrated statistically significant improvement over the vehicle foam on the trial’s primary and multiple secondary endpointsOnce-daily roflumilast foam demonstrated a favorable safety and tolerability profileRoflumilast foam potential “Best in Class” topical PDE4 inhibitorSeborrheic dermatitis affects 10 million U.S. patientsCompany to host a conference call today at 8:30 a.m. EST WESTLAKE VILLAGE, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced positive topline data from its Phase 2 clinical trial evaluating ARQ-154 (topical roflumilast foam) as a potential treatment for seborrheic dermatitis.\n Roflumilast foam 0.3% administered once daily for 8 weeks demonstrated statistically significant improvement compared to a matching vehicle foam on key efficacy endpoints in subjects with moderate-to-severe seborrheic dermatitis. On the study’s primary endpoint assessed at week 8, roflumilast foam 0.3% achieved an Investigator Global Assessment (IGA) success rate of 73.8% compared to a vehicle rate of 40.9% (p","length":2507,"tagName":"div"}]